177Lu-LNC1004 / Dongcheng Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
177Lu-LNC1004 / Dongcheng Pharma
NCT05400967: Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

Recruiting
1
10
RoW
68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Peking Union Medical College Hospital
177Lu-EB-FAPI
01/25
04/25
CISPD-5, NCT06081322: A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Recruiting
1
29
RoW
PRRT with 177Lu-EB-FAPI
Zhejiang University
Advanced Pancreatic Cancer and Cholangiocarcinoma
06/24
06/25
NCT05723640: The Safety and Dosimetry Study of 177Lu-LNC1004 Injection

Recruiting
1
24
RoW
177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy, 177Lu-LNC1004 Injection group 4 radionuclide therapy
Yantai LNC Biotechnology Singapore PTE. LTD.
Solid Tumor, Unspecified, Adult
03/25
03/25

Download Options